Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Myeloproliferative Disorders 6Carcinoma, Non-Small-Cell Lung 5Primary Myelofibrosis 4Hematologic Neoplasms 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Hodgkin Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Polycythemia Vera 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Doxorubicin 19Ifosfamide 12Radiotherapy 11pembrolizumab 6Nivolumab 6Ipilimumab 6pazopanib 4Specimen Handling 4Radiation 4Gemcitabine 4Docetaxel 4CTLA-4 Antigen 4Biopsy 4Trabectedin 3Sunitinib 3Magnetic Resonance Spectroscopy 3pegfilgrastim 2liposomal doxorubicin 2cabozantinib 2brostallicin 2X-Rays 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Methotrexate 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Diathermy 2Cisplatin 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Histiocytoma, Malignant Fibrous × itacitinib × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡